Dr. Garland is a thoracic medical oncologist and translational researcher with expertise in lung cancer and mesothelioma. She serves as Director, Clinical Research in Thoracic Oncology and Interim Director, Early Phase Drug Development at the University of Arizona Cancer Center, a NCI-designated Comprehensive Cancer Center.
Dr. Garland has designed investigator-initiated translational clinical trials with novel targeted agents in advanced lung cancer and mesothelioma. She participates in chemoprevention efforts at the Cancer Center through serving as Co-Investigator and Medical Director of the N01-supported University of Arizona Cancer Center’s Cancer Prevention Consortium and the PI on sequential NCI-funded lung cancer prevention trials. She participates in translational collaboration with several basic scientists in preclinical development of novel cancer agents and imaging biomarkers.
Further, Dr. Garland collaborates with University of Arizona Biomedical Engineering in serving as a co-investigator for a randomized trial of a novel exercise intervention for cancer patients with peripheral neuropathy that provides evidence of improved balance outcomes relevant to fall prevention with the novel exercise intervention.
Dr. Garland previously served for 10 years on the University of Arizona IRB and currently serves as Chair of the University of Arizona Cancer Center Scientific Review Committee.
Non-small cell lung cancer, small cell lung cancer, mesothelioma, head and neck cancer, thyroid cancer.
My clinical and research interests are in experimental therapeutics, with a focus on malignant diseases of the chest. These include lung cancer, mesothelioma, and rarer mediastinal tumors. In general, both small cell and non-small cell lung cancers are difficult to diagnose at an early stage, once advanced, they are highly lethal malignancies. Standard chemotherapy offers palliative benefit, but only limited survival benefit for lung cancer patients.
Novel targets for therapeutic design, including targets in signal transduction pathways and in pathways conferring drug resistance, are being identified. We are designing trials using new chemotherapy agents and small molecules that are able to inhibit more selectively the activity of these targets, thus providing more potent anticancer activity with less normal tissue toxicity.
Appropriate targets in an individual lung cancer patient's tumor may be able to be defined using molecular biologic assays of tumor tissue, therefore allowing more finely tuned therapy for that individual.
- Garland L, Taylor C, Pilkington D, Cohen J, Von Hoff D. A Phase I Pharmacokinetic Study of HMN-214, a Novel Oral Stilbene Derivative With Polo-Like Kinase-1 Interacting Properties, in Patients With Advanced Solid Tumors. Clin Cancer Res 2006:12;5182-9.
- Garland L, Rankin C, Gandara D, Rivkin S, Scott K, Nagle R, Altomare D, Klein-Szanto A, Testa R, Borden E. A Phase II study of oral EGFR tyrosine kinase inhibitor erlotinib in patients with malignant pleural mesothelioma: A Southwest Oncology Group Study. J Clin Oncol 2007:25;2406-2413.
- Herbst RS, Davies A, Natale R, Dang T, Murren J, Schiller J, Garland L, Miller V, Mendelson D, Van den Abbeele A, Melenevsky Y, de Vries D, Eberhard D, Lyons B, Lutzker S, Johnson BE. Efficacy and Safety of Single Agent Pertuzumab, a HER Dimerization Inhibitor, in Patients with Non–Small-Cell Lung Cancer. Clin Cancer Res 2007:13;6175-81.
- Nguyen NP, Garland L, Welsh J, Hamilton R, Cohen D, Vincent V. Can Stereotactic Fractionated Radiation Therapy Become the Standard of Care for Early-Stage Non-Small Cell Lung Cancer? Cancer Treat Rev 2008;34(8):719-27.
American Board of Medical Oncology